ResMed Inc
RMD: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$642.00 | Tkrqy | Lszgjmbt |
ResMed: Market Concerns Regarding Weight Loss Drugs Are Overblown
Eli Lilly released results from its SURMOUNT-OSA clinical trial, which have reignited concerns that GLP-1 drugs may disrupt the sleep apnea industry. However, we think these concerns are overblown. Shares in narrow-moat ResMed remain undervalued versus our unchanged USD 264 fair value estimate, or AUD 40 per CDI at current exchange rates.